title: Omidenepag
text: # Omidenepag
  
  Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension.
  
  Omidenepag was approved for medical use in Japan in 2018, and in the United States in September 2022.
  
  ## Medical uses
  
  Omidenepag is indicated for the treatment of glaucoma and ocular hypertension.
  
  ## Adverse effects
  
  The most common adverse effects of omidenepag are conjunctival hyperemia and macular edema, including cystoid macular edema.
  
  ## Pharmacology
  
  Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag. Omidenepag is a selective prostaglandin E2 receptor agonist.
  
  ## History
  
  Omidenepag was developed by Ube Industries and Santen Pharmaceutical.
  
  